临床试验/EUCTR2004-001125-20-IT

EUCTR2004-001125-20-IT进行中（未招募）不适用

First International Randomized trial in Metastatic Adrenocortical Cancer Treatment FIRM-ACT Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane

AZIENDA OSPEDALIERA S. LUIGI GONZAGA0 个研究点目标入组 300 人开始时间: 2007年1月15日最近更新: 2012年8月28日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

未提供

研究者

发起方

AZIENDA OSPEDALIERA S. LUIGI GONZAGA

相似试验

First International Randomised trial in Locally Advanced and Metastatic Adrenocortical Cancer Treatment - Etoposide, Doxorubicin, Cisplatin and Mitotane versus Streptozotocin and MitotaneAdrenocortical CarcinomaCancerAdrenocortical carcinoma

ISRCTN94256573Collaborative group for Adrenocortical Carcinoma Therapy (CO-ACT) (Germany)300

进行中（未招募）

First International Randomized Study in MAlignant Progressive Pheochromocytoma and ParagangliomaDiagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses: 1. diagnosis of PPGL from histopathological review of resected or biopsied tissue performed by a skilled pathologist or 2. in patients where tumor tissue is unavailable for formal pathological review, from combined biochemical and functional imaging evidence of PPGLMedDRA version: 16.0Level: LLTClassification code 10033792Term: Paraganglion neoplasm NOSSystem Organ Class: 100000004864

EUCTR2010-024621-20-ITInstitut Gustave Roussy74

进行中（未招募）

First International Randomized Study in MAlignant Progressive Pheochromocytoma and ParagangliomaDiagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses: 1. diagnosis of PPGL from histopathological review of resected or biopsied tissue performed by a skilled pathologist or 2. in patients where tumor tissue is unavailable for formal pathological review, from combined biochemical and functional imaging evidence of PPGLMedDRA version: 14.1Level: LLTClassification code 10033792Term: Paraganglion neoplasm NOSSystem Organ Class: 100000004864

EUCTR2010-024621-20-NLInstitut Gustave Roussy74

First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paragangliomapheochromocytoma/paraganglioma1002911210014713

NL-OMON37272Institut Gustave Roussy8

进行中（未招募）

First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

EUCTR2005-004137-18-ATCollaborative group for Adrenocortical Carcinoma Therapy (COAT)300